FiercePharma's most popular stories of 2008

Welcome to FiercePharma's look back at our most popular stories and features of 2008. While a number of topics are represented in our top 10 stories, layoffs seem to be a recurring theme. A host of companies eliminated employees this year, though sales reps seemed to take the brunt of the cutbacks. The interest in downsizing also pushed our second annual layoffs report to the top of our features list, while the report on CEO's ample paychecks came in a close second.

Highlighting the growing emphasis of disclosure, NPR radio host Dr. Frederick K. Goodwin's failure to report $1.3 million in drugmakers payments was the most-read FiercePharma article in 2008. Concerns about Gardasil, and the ability of certain drugmakers to replenish their pipelines rounded out our most-read list.

Top 10 stories of 2008

  • NPR doc didn't disclose pharma payments

  • Gardasil side effects prompt CDC study

  • Amgen, Schering-Plough most likely to replenish pipeline

  • Pharma sales undergo major shift

  • Merck to cut 7,200 jobs

  • Ranks of sales reps thinning

  • Will Pfizer layoffs hit again in January?

  • Biogen: Tysabri patients have PML

  • CEO: Novartis plans big restructuring

  • Hinting at layoffs, Pfizer extends severance

Top 5 features of 2008

  • Top 5 layoffs of 2008

  • Top 17 paychecks in Big Pharma

  • Best pharma stocks of 2007

  • Worst pharma stocks of 2007

  • Top 10 Drug Warnings and Recalls of 2007

FiercePharma's most popular stories of 2008

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.